Search

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more